Skip to main content

RT @DrCassySims: Does Bimekizumab, anti-IL17F, work in PsA? #ACR22 @RheumNow Abstract #L02 💊Phase 3, randomized, p

Nov 13, 2022 1:33 pm
Social Author Name
Catherine Sims, MD
Tweet Content
Does Bimekizumab, anti-IL17F, work in PsA? #ACR22 @RheumNow Abstract #L02 💊Phase 3, randomized, placebo-controlled study 💉Biologic naive patients ✋ Week 52: 53-54% BKZ groups achieved ACR502 (v. 50% in TNFi) 📍benefits sustained to week 52 🛑No new safety signals
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×